AU2001252235A1 - A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer - Google Patents

A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer

Info

Publication number
AU2001252235A1
AU2001252235A1 AU2001252235A AU5223501A AU2001252235A1 AU 2001252235 A1 AU2001252235 A1 AU 2001252235A1 AU 2001252235 A AU2001252235 A AU 2001252235A AU 5223501 A AU5223501 A AU 5223501A AU 2001252235 A1 AU2001252235 A1 AU 2001252235A1
Authority
AU
Australia
Prior art keywords
camptothecin
cancer
treatment
composition
alkylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252235A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001252235A1 publication Critical patent/AU2001252235A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001252235A 2000-03-17 2001-03-14 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer Abandoned AU2001252235A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19000700P 2000-03-17 2000-03-17
US60190007 2000-03-17
PCT/EP2001/003500 WO2001068066A2 (en) 2000-03-17 2001-03-14 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2001252235A1 true AU2001252235A1 (en) 2001-09-24

Family

ID=22699678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252235A Abandoned AU2001252235A1 (en) 2000-03-17 2001-03-14 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer

Country Status (6)

Country Link
US (1) US6548488B2 (enExample)
EP (1) EP1267873A2 (enExample)
JP (1) JP2003526659A (enExample)
AR (1) AR027677A1 (enExample)
AU (1) AU2001252235A1 (enExample)
WO (1) WO2001068066A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796689A4 (en) * 2004-09-20 2009-01-14 British Columbia Cancer Agency GEMCITABINE FREE OR ENCAPSULATED IN LIPOSOMES ONLY OR IN ASSOCIATION WITH FREE IDARUBICIN OR ENCAPSULATED IN LIPOSOMES
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
AU2007212201B2 (en) * 2006-02-09 2012-09-13 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
RU2009133793A (ru) 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
EP0540099B1 (en) 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin

Also Published As

Publication number Publication date
JP2003526659A (ja) 2003-09-09
AR027677A1 (es) 2003-04-09
US6548488B2 (en) 2003-04-15
US20010056082A1 (en) 2001-12-27
WO2001068066A2 (en) 2001-09-20
EP1267873A2 (en) 2003-01-02
WO2001068066A3 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AU5326100A (en) Pharmaceutical compositions and methods for use
EP1176964B8 (en) Uses of et743 for treating cancer
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU7377200A (en) Combination therapy including camptothecin
AU2460100A (en) Masking agent
AU2002215300A1 (en) Cancer chemotherapeutical and chemopreventive agent
AU1554301A (en) Radioprotecting agent
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
AU2001232345A1 (en) Compositions for preventing and treating digestive diseases
AU2001252235A1 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU1602902A (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU4874301A (en) Medicinal compositions containing camptothecin derivative and ph regulating agent
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001275696A1 (en) Therapeutic agent
AU7919100A (en) Clear hair-treatment agent